title: Pharmacologic management of myxomatous mitral valve disease in dogs.
abstract: Myxomatous mitral valve disease (MMVD) causing mitral regurgitation is the most important disease of the heart in small animal cardiovascular medicine. Because MMVD is an example of a chronic disease that progresses from mild to severe over years, treatment strategies change with the stage of the disease. In this review the treatment options are compared and contrasted as they are discussed relative to the recently published ACVIM consensus statement regarding the treatment of MMVD. Results from clinical trials and evidence-based medicine are likely to provide significant improvements in the management of MMVD in the coming decades.
authors.affiliation: Department of Clinical Sciences, North Carolina State University, Raleigh, NC, USA. clarke_atkins@ncsu.edu
authors.forename: Clarke E
authors.initials: CE
authors.lastname: Atkins
authors.forename: Jens
authors.initials: J
authors.lastname: Häggström
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D008944:Mitral Valve Insufficiency / Q000188:drug therapy / Q000662:veterinary*
chemical_list: D002317:Cardiovascular Agents